This prospective, randomized, double-blind, placebo-controlled trial examined the efficacy of intravenous lidocaine in the treatment of fibromyalgia. Patients rated their pain scores prior to treatment or placebo infusion. The treatment (or placebo) was repeated 2 weeks later along with a report of pain scores after the second treatment and again 2 weeks and 6 weeks after the last treatment. Patients receiving the lidocaine infusion reported significantly improved pain scores 2 weeks after last infusion. The reduced pain scores lasted for approximately 4 weeks after last infusion and returned to baseline approximately 6 weeks after last infusion.